ATE318322T1 - Virale kernproteine-kationische lipid- nukleinsäure-verabreichungkomplexe - Google Patents
Virale kernproteine-kationische lipid- nukleinsäure-verabreichungkomplexeInfo
- Publication number
- ATE318322T1 ATE318322T1 AT00981481T AT00981481T ATE318322T1 AT E318322 T1 ATE318322 T1 AT E318322T1 AT 00981481 T AT00981481 T AT 00981481T AT 00981481 T AT00981481 T AT 00981481T AT E318322 T1 ATE318322 T1 AT E318322T1
- Authority
- AT
- Austria
- Prior art keywords
- cationic lipid
- noi
- complexes
- nucleic acid
- core proteins
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- -1 cationic lipid Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9930533.6A GB9930533D0 (en) | 1999-12-23 | 1999-12-23 | Nucleic acid delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE318322T1 true ATE318322T1 (de) | 2006-03-15 |
Family
ID=10866964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00981481T ATE318322T1 (de) | 1999-12-23 | 2000-12-12 | Virale kernproteine-kationische lipid- nukleinsäure-verabreichungkomplexe |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20030153081A1 (de) |
| EP (2) | EP1566445A3 (de) |
| JP (1) | JP2003518388A (de) |
| CN (1) | CN100354426C (de) |
| AT (1) | ATE318322T1 (de) |
| AU (1) | AU781356B2 (de) |
| CA (1) | CA2395454A1 (de) |
| CZ (1) | CZ298353B6 (de) |
| DE (1) | DE60026164T2 (de) |
| DK (1) | DK1244805T3 (de) |
| ES (1) | ES2258986T3 (de) |
| GB (1) | GB9930533D0 (de) |
| PT (1) | PT1244805E (de) |
| RU (1) | RU2267536C2 (de) |
| UA (1) | UA77393C2 (de) |
| WO (1) | WO2001048233A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0118517D0 (en) * | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
| FR2829136B1 (fr) * | 2001-08-29 | 2006-11-17 | Aventis Pharma Sa | Derives lipidiques d'aminoglycosides |
| EP1430074B1 (de) * | 2001-08-29 | 2009-05-06 | Aventis Pharma S.A. | Lipid-aminoglykosid konjugate zur transfektion |
| AU2004246904B2 (en) | 2003-06-18 | 2010-02-04 | Biolab Ltd. | Sphingolipids polyalkylamine conjugates for use in transfection |
| US7906122B2 (en) | 2003-06-18 | 2011-03-15 | Yissum Research Development Company Of The Hebrew University Of Jersusalem | Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination |
| GB0418172D0 (en) * | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
| US20090155853A1 (en) * | 2005-11-18 | 2009-06-18 | Gary Nabel | Non-viral gene delivery complex |
| WO2008052766A2 (en) * | 2006-11-03 | 2008-05-08 | Medigene Ag | Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases |
| WO2008056623A1 (en) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Composition for introduction of nucleic acid |
| EP2105145A1 (de) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide |
| WO2010042751A2 (en) * | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
| EP4241767B1 (de) | 2008-11-10 | 2024-10-23 | Arbutus Biopharma Corporation | Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika |
| WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
| JP2014527072A (ja) | 2011-09-09 | 2014-10-09 | バイオメド リアルティー, エル.ピー. | ウイルスタンパク質の集合を制御するための方法および組成物 |
| ES3065854T3 (en) | 2011-12-07 | 2026-05-08 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| IL316479A (en) | 2014-06-25 | 2024-12-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| JP2018526321A (ja) | 2015-04-27 | 2018-09-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 適応免疫応答を誘導するためのヌクレオシド修飾rna |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| US10829787B2 (en) * | 2015-10-14 | 2020-11-10 | Life Technologies Corporation | Ribonucleoprotein transfection agents |
| RS63986B1 (sr) | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| WO2017212006A1 (en) * | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| CN109475640B (zh) | 2016-06-09 | 2023-03-10 | 库瑞瓦格欧洲公司 | 核酸被运载物的混合载运体 |
| CA3031702A1 (en) | 2016-07-27 | 2018-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Immolative cell-penetrating complexes for nucleic acid delivery |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| BR112019014314A2 (pt) | 2017-01-11 | 2020-02-18 | The Trustees Of The University Of Pennsylvania | Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika. |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CA3061326A1 (en) | 2017-04-27 | 2018-11-01 | The Johns Hopkins University | Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus |
| ES2981244T3 (es) | 2017-04-28 | 2024-10-07 | Acuitas Therapeutics Inc | Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| EP4501322A3 (de) | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipide zur verwendung in lipidnanopartikelformulierungen |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| US12583816B2 (en) | 2018-10-18 | 2026-03-24 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| JP7523449B2 (ja) | 2019-01-11 | 2024-07-26 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| JP7630904B2 (ja) * | 2019-07-23 | 2025-02-18 | 株式会社東芝 | 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法 |
| CN110408656A (zh) * | 2019-07-29 | 2019-11-05 | 成都朴名生物科技有限公司 | 脂多聚物体及其制备方法、采用脂多聚物体将基因编辑质粒导入真核细胞的方法 |
| CN110452303B (zh) * | 2019-08-08 | 2022-03-04 | 中国科学院武汉病毒研究所 | 共价连接核酸和肽或蛋白的方法及应用 |
| CN111394313A (zh) * | 2020-04-01 | 2020-07-10 | 河南科技学院 | 一种人造细胞及其制备方法 |
| JP7798855B2 (ja) | 2020-07-16 | 2026-01-14 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子に使用するためのカチオン性脂質 |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CN114656422B (zh) * | 2022-04-22 | 2023-05-23 | 重庆理工大学 | 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1322987A (en) * | 1969-12-29 | 1973-07-11 | Richter Gedeon Vegyeszet | On,n-diacylhydroxylamine derivatives and preparation |
| US4189431A (en) * | 1975-08-04 | 1980-02-19 | The Board of Trustees of Leland Stanford Junior University | Alkinyl terminating groups in biogenetic-like cyclizations to steroids |
| US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
| US5510510A (en) * | 1994-05-10 | 1996-04-23 | Bristol-Meyers Squibb Company | Inhibitors of farnesyl protein transferase |
| EP0874910A4 (de) * | 1995-06-07 | 1999-04-21 | Life Technologies Inc | Durch peptide erhöhte kationische lipid transfektionen |
| US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| CN1181422A (zh) * | 1996-10-31 | 1998-05-13 | 上海市肿瘤研究所 | 与生长因子受体结合的多肽所构建的基因转移载体 |
| JP2002539134A (ja) * | 1999-03-09 | 2002-11-19 | アクゾ・ノベル・エヌ・ベー | 減数分裂の阻害のための22r−ヒドロキシコレスタ−8,14−ジエン誘導体 |
-
1999
- 1999-12-23 GB GBGB9930533.6A patent/GB9930533D0/en not_active Ceased
-
2000
- 2000-12-12 DE DE60026164T patent/DE60026164T2/de not_active Expired - Fee Related
- 2000-12-12 DK DK00981481T patent/DK1244805T3/da active
- 2000-12-12 CA CA002395454A patent/CA2395454A1/en not_active Abandoned
- 2000-12-12 EP EP04077588A patent/EP1566445A3/de not_active Withdrawn
- 2000-12-12 CZ CZ20022193A patent/CZ298353B6/cs not_active IP Right Cessation
- 2000-12-12 EP EP00981481A patent/EP1244805B1/de not_active Expired - Lifetime
- 2000-12-12 AT AT00981481T patent/ATE318322T1/de not_active IP Right Cessation
- 2000-12-12 RU RU2002119560/13A patent/RU2267536C2/ru not_active IP Right Cessation
- 2000-12-12 PT PT00981481T patent/PT1244805E/pt unknown
- 2000-12-12 ES ES00981481T patent/ES2258986T3/es not_active Expired - Lifetime
- 2000-12-12 US US10/168,909 patent/US20030153081A1/en not_active Abandoned
- 2000-12-12 JP JP2001548745A patent/JP2003518388A/ja active Pending
- 2000-12-12 AU AU18716/01A patent/AU781356B2/en not_active Ceased
- 2000-12-12 UA UA2002076053A patent/UA77393C2/uk unknown
- 2000-12-12 WO PCT/GB2000/004767 patent/WO2001048233A1/en not_active Ceased
- 2000-12-12 CN CNB008191468A patent/CN100354426C/zh not_active Expired - Fee Related
-
2008
- 2008-10-30 US US12/261,999 patent/US20090209037A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2002119560A (ru) | 2004-03-27 |
| EP1244805B1 (de) | 2006-02-22 |
| RU2267536C2 (ru) | 2006-01-10 |
| ES2258986T3 (es) | 2006-09-16 |
| AU781356B2 (en) | 2005-05-19 |
| CZ20022193A3 (cs) | 2003-02-12 |
| CZ298353B6 (cs) | 2007-09-05 |
| US20030153081A1 (en) | 2003-08-14 |
| PT1244805E (pt) | 2006-07-31 |
| JP2003518388A (ja) | 2003-06-10 |
| CN100354426C (zh) | 2007-12-12 |
| DE60026164T2 (de) | 2006-11-16 |
| US20090209037A1 (en) | 2009-08-20 |
| AU1871601A (en) | 2001-07-09 |
| DE60026164D1 (de) | 2006-04-27 |
| EP1566445A2 (de) | 2005-08-24 |
| CA2395454A1 (en) | 2001-07-05 |
| EP1566445A3 (de) | 2005-08-31 |
| EP1244805A1 (de) | 2002-10-02 |
| GB9930533D0 (en) | 2000-02-16 |
| WO2001048233A1 (en) | 2001-07-05 |
| CN1434870A (zh) | 2003-08-06 |
| DK1244805T3 (da) | 2006-06-26 |
| UA77393C2 (en) | 2006-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60026164D1 (de) | Virale kernproteine-kationische lipid-nukleinsäure-verabreichungkomplexe | |
| WO2000073316A3 (en) | Virus immunologic determinants | |
| NZ521396A (en) | Fusion proteins comprising two or more Neisseria polypeptides | |
| FI941473A0 (fi) | Uusia konjugaatteja nukleiinihappojen viemiseksi korkeampiin eukaryoottisiin soluihin | |
| CA2305013A1 (en) | Fusion proteins comprising hiv-1 tat and/or nef proteins | |
| CA2020668A1 (en) | Fused or hybrid protein comprising viral antigen and lymphokine | |
| NO20002800L (no) | Cyklosporinholdig mikroemulsjon, for konsentratsammensetning | |
| AU3192889A (en) | T cell activation markers | |
| AUPN999096A0 (en) | Peptides, antibodies, vaccines & uses thereof | |
| FR2799758B1 (fr) | Complexe a base d'acide orthosilicique biologiquement assimilable, se presentant sous forme solide, stable et concentree, et procede de preparation | |
| WO1997031934A3 (de) | Neue metabolisierbare lipopolyamine, deren darstellung und anwendung | |
| WO1999067382A3 (en) | Angiopoietin-like growth factor sequences | |
| WO1997040147A8 (en) | Antigenically reactive regions of the hepatitis a virus polyprotein | |
| AU630861B2 (en) | Recombinant hiv-2 polypeptides | |
| WO2000063385A3 (en) | Nucleic acid immunization | |
| PT1165797E (pt) | Partículas para a terapia genética | |
| DK0442372T3 (da) | Forbedrede mærkede haptener, fremgangsmåde til deres fremstilling samt anvendelse af disse mærkede haptener ved immunoassays | |
| WO2000061747A3 (en) | Clasp-2 transmembrane proteins | |
| AU3282900A (en) | Target cell-specific, multivalent proteins (mvp) | |
| DE60026666D1 (de) | Induktion von antigen-spezifischen T-Zellen durch Interferon | |
| WO2003093440A3 (en) | Methods and compositions for expressing a nucleic acid in a dendritic cell | |
| WO2002083896A3 (en) | Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same | |
| CY1105693T1 (el) | Συμπλοκα μεταφορας πρωτεϊνης ιικου πυρηνα-κατιοντικου λιπιδιου-νουκλεϊνικου οξεος | |
| WO2001042297A3 (en) | Clasp-3 transmembrane protein | |
| BR0016740A (pt) | Antìgenos de esporozoìto de cryptosporidium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1244805 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |